In this observational, non-invasive clinical study different neurobiological analyses will be performed in a group of patients with severe treatment resistant major depression participating in an efficacy study of deep brain stimulation of the superolateral branch of the medial forebrain bundle (slMFB) - FORESEE III.
This study is a sub-project of the FORESEE III study (Controlled Randomized Clinical Trial to assess Efficacy of Deep Brain Stimulation (DBS) of the slMFB in Patients with Treatment Resistant Major Depression). The FORESEE III study itself is a randomized, sham-controlled, double blind (patient and observer blinded) clinical trial to assess the antidepressant effect of DBS compared to sham. The aim of this sub-project is to analyze the time-course of biological correlates of treatment resistant major depression as well as neurobiological markers of treatment response to treatment with DBS in a well-characterized patient population during 12 month of DBS. Specific neurobiological analyses include testing of 1. epigenetic markers (DNA methylation in candidate genes of depression and epigenome-wide association studies, EWAS) 2. markers of neuroinflammation (cytokines, neuropeptides and other immune factors) 3. micro RNAs and transcriptome signatures 4. markers of neurodegeneration (neurofilament light protein) 5. metabolomic analyses and 6. endocrinological parameters including glucose tolerance. All markers will be tested in blood samples (and urine samples for metaboloic profiling) before neurosurgery as well as at several time points during DBS and sham condition intervals. Additionally hemodynamic parameters will be analysed at test stimulation of the slMFB during neurosurgery. The results will be correlated with clinical and other biological response parameters of the FORESEE III study and are hypothesized to indicate treatment response as well as allowing prediction of response to DBS. All neurobiological analyses will be linked in a tightly integrated and comprehensive translational approach. Further, a volunteer group of healthy controls will be recruited and tested for blood-markers of neurodegeneration (neurofilament light protein, 4.) as well as metabolomic analyses in blood and urine (5.).
Study Type
OBSERVATIONAL
Enrollment
50
University Hospital Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
RECRUITINGChange from baseline in DNA methylation patterns in plasma at 1 month of deep brain stimulation (DBS)
Epigenetic mechanisms such as DNA methylation crucially govern gene function and have been shown to be temporally dynamic and responsive to environmental stress. Epigenetic patterns in blood, saliva or other peripheral material have been suggested to partly reflect central epigenetic processes. DNA will by isolated and undergo bisulfite conversion. Using pyro- and direct sequencing, samples will be analyzed for DNA methylation in candidate genes of depression.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 1 month of DBS (week 5 group A, week 21 group B)
Change from baseline in DNA methylation patterns in plasma at 4 month of deep brain stimulation (DBS)
Epigenetic mechanisms such as DNA methylation crucially govern gene function and have been shown to be temporally dynamic and responsive to environmental stress. Epigenetic patterns in blood, saliva or other peripheral material have been suggested to partly reflect central epigenetic processes. DNA will by isolated and undergo bisulfite conversion. Using pyro- and direct sequencing, samples will be analyzed for DNA methylation in candidate genes of depression.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 4 month of DBS (week 17 group A, week 33 group B)
Change from baseline in DNA methylation patterns in plasma at 12 month of deep brain stimulation (DBS)
Epigenetic mechanisms such as DNA methylation crucially govern gene function and have been shown to be temporally dynamic and responsive to environmental stress. Epigenetic patterns in blood, saliva or other peripheral material have been suggested to partly reflect central epigenetic processes. DNA will by isolated and undergo bisulfite conversion. Using pyro- and direct sequencing, samples will be analyzed for DNA methylation in candidate genes of depression.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 12 month of DBS (end of study both groups)
Change from baseline in neuroinflammatory and neuropeptide patterns at 1 month of deep brain stimulation (DBS)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
A new method of analysis (Proseek® Multiplex Inflammation, Olink Bioscience, Uppsala, Sweden) will be used to determine any change in patterns of relevant neuropeptides and inflammatory markers. This multiplex proximity extension assay (PEA) will simultaneously analyze 92 different proteins, including cytokines, neuropeptides and other immune factors.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 1 month of DBS (week 5 group A, week 21 group B)
Change from baseline in neuroinflammatory and neuropeptide patterns at 4 month of deep brain stimulation (DBS)
A new method of analysis (Proseek® Multiplex Inflammation, Olink Bioscience, Uppsala, Sweden) will be used to determine any change in patterns of relevant neuropeptides and inflammatory markers. This multiplex proximity extension assay (PEA) will simultaneously analyze 92 different proteins, including cytokines, neuropeptides and other immune factors.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 4 month of DBS (week 17 group A, week 33 group B)
Change from baseline in neuroinflammatory and neuropeptide patterns at 12 month of deep brain stimulation (DBS)
A new method of analysis (Proseek® Multiplex Inflammation, Olink Bioscience, Uppsala, Sweden) will be used to determine any change in patterns of relevant neuropeptides and inflammatory markers. This multiplex proximity extension assay (PEA) will simultaneously analyze 92 different proteins, including cytokines, neuropeptides and other immune factors.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 12 month of DBS (end of study both groups)
Change from baseline in transcriptome profiles at 1 month of deep brain stimulation (DBS)
A massive parallel next generation deep sequencing (NGS) technology will be used followed by bioinformatic network analysis to determine intraindividual changes in exosomal miR ( (miRs, 19-22 nt long non-coding RNAs) and transcriptome profiles.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 1 month of DBS (week 5 group A, week 21 group B)
Change from baseline in exosomal Micro-RNA (miR) expression levels and transcriptome profiles at 4 month of deep brain stimulation (DBS)
A massive parallel next generation deep sequencing (NGS) technology will be used followed by bioinformatic network analysis to determine intraindividual changes in exosomal miR ( (miRs, 19-22 nt long non-coding RNAs) and transcriptome profiles.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 4 month of DBS (week 17 group A, week 33 group B)
Change from baseline in exosomal Micro-RNA (miR) expression levels and transcriptome profiles at 12 month of deep brain stimulation (DBS)
A massive parallel next generation deep sequencing (NGS) technology will be used followed by bioinformatic network analysis to determine intraindividual changes in exosomal miR ( (miRs, 19-22 nt long non-coding RNAs) and transcriptome profiles.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 12 month of DBS (end of study both groups)
Change from baseline in plasma levels of Neurofilament light protein at 2 days before surgical device implantation
Neurofilament light protein is part of the neuroaxonal cytoskeleton and can be released into plasma following neuroaxonal damage. In plasma it will be measured by single-molecule array (SiMoA) assays.
Time frame: At baseline (up to 10 to 7 weeks before surgical device implantation) and at 2 days before surgical device implantation
Change from baseline in plasma levels of Neurofilament light protein at 1 month of deep brain stimulation (DBS)
Neurofilament light protein is part of the neuroaxonal cytoskeleton and can be released into plasma following neuroaxonal damage. In plasma it will be measured by single-molecule array (SiMoA) assays.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 1 month of DBS (week 5 group A, week 21 group B)
Change from baseline in plasma levels of Neurofilament light protein at 4 month of deep brain stimulation (DBS)
Neurofilament light protein is part of the neuroaxonal cytoskeleton and can be released into plasma following neuroaxonal damage. In plasma it will be measured by single-molecule array (SiMoA) assays.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 4 month of DBS (week 17 group A, week 33 group B)
Change from baseline in plasma levels of Neurofilament light protein at 12 month of deep brain stimulation (DBS)
Neurofilament light protein is part of the neuroaxonal cytoskeleton and can be released into plasma following neuroaxonal damage. In plasma it will be measured by single-molecule array (SiMoA) assays.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 12 month of DBS (end of study both groups)
Change from baseline in metabolite profiles in plasma and urine at 1 month of deep brain stimulation (DBS)
Metabolite profiles of plasma and urine samples will be analysed by chromatographic separation techniques, different mass spectrometric ionization modes and mass analyzers in order to assess molecular changes in the metabolome. The metabolomic methodologies may include fingerprinting, nontargeted, and targeted approaches, metabolic profiling and metabolic flux analysis.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 1 month of DBS (week 5 group A, week 21 group B)
Change from baseline in metabolite profiles in plasma and urine at 4 month of deep brain stimulation (DBS)
Metabolite profiles of plasma and urine samples will be analysed by chromatographic separation techniques, different mass spectrometric ionization modes and mass analyzers in order to assess molecular changes in the metabolome. The metabolomic methodologies may include fingerprinting, nontargeted, and targeted approaches, metabolic profiling and metabolic flux analysis.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 4 month of DBS (week 17 group A, week 33 group B)
Change from baseline in metabolite profiles in plasma and urine at 12 month of deep brain stimulation (DBS)
Metabolite profiles of plasma and urine samples will be analysed by chromatographic separation techniques, different mass spectrometric ionization modes and mass analyzers in order to assess molecular changes in the metabolome. The metabolomic methodologies may include fingerprinting, nontargeted, and targeted approaches, metabolic profiling and metabolic flux analysis.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at 12 month of DBS (end of study both groups)
Change from baseline in insuline resistance at week 41
An oral glucose tolerance test with blood measures of glucose, insulin and c-peptide at several time points during a period of 3 hours after oral intake of 75g glucose will be performed.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at week 41 (both groups)
Change from baseline in systemic metabolic parameters at week 41
Different systemic metabolic parameters will be measured in blood.
Time frame: At baseline (up to 10 weeks before surgical device implantation) and at week 41 (both groups)
Cardiac stroke volume (ml)
Measured with ClearSight System, Edwards Lifesciences (allowing non-invasive and real-time continuous hemodynamic monitoring).
Time frame: At test stimulation of the slMFB during neurosurgery
Non-invasive blood pressure (mmHG)
Measured with ClearSight System, Edwards Lifesciences (allowing non-invasive and real-time continuous hemodynamic monitoring).
Time frame: At test stimulation of the slMFB during neurosurgery
Cardiac stroke volume variation (%)
Measured with ClearSight System, Edwards Lifesciences (allowing non-invasive and real-time continuous hemodynamic monitoring)
Time frame: At teststimulation of the slMFB during neurosurgery
Systemic vascular resistance (mmHg⋅min⋅mL-1)
Measured with ClearSight System, Edwards Lifesciences (allowing non-invasive and real-time continuous hemodynamic monitoring).
Time frame: At test stimulation of the slMFB during neurosurgery